{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T06:11:22Z","timestamp":1787724682390,"version":"build-2784847793"},"update-to":[{"DOI":"10.1002\/14651858.cd010292","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2018,2,28]],"date-time":"2018-02-28T00:00:00Z","timestamp":1519776000000}}],"reference-count":142,"publisher":"Wiley","issue":"7","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd010292.pub2","type":"journal-article","created":{"date-parts":[[2018,2,28]],"date-time":"2018-02-28T16:12:15Z","timestamp":1519834335000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":54,"title":["Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia"],"prefix":"10.1002","volume":"2020","author":[{"given":"Patrick","family":"Welsch","sequence":"additional","affiliation":[{"name":"Health Care Center for Pain Medicine and Mental Health; Saarbr\u00fccken Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nurcan","family":"\u00dc\u00e7eyler","sequence":"additional","affiliation":[{"name":"Department of Neurology; University of W\u00fcrzburg; W\u00fcrzburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Klose","sequence":"additional","affiliation":[{"name":"Department of Internal and Integrative Medicine, Kliniken Essen-Mitte, Faculty of Medicine; University of Duisburg-Essen; Essen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Walitt","sequence":"additional","affiliation":[{"name":"National Institute of Nursing Research; National Institutes of Health; Bethesda MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winfried","family":"H\u00e4user","sequence":"additional","affiliation":[{"name":"Department of Psychosomatic Medicine and Psychotherapy; Technische Universit\u00e4t M\u00fcnchen; M\u00fcnchen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,2,28]]},"reference":[{"issue":"9","key":"10.1002\/14651858.CD010292.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1002\/art.20485","article-title":"A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder","volume":"50","author":"Arnold","year":"2004","journal-title":"Arthritis and Rheumatism"},{"issue":"1-3","key":"10.1002\/14651858.CD010292.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.pain.2005.06.031","article-title":"A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder","volume":"119","author":"Arnold","year":"2005","journal-title":"Pain"},{"issue":"12","key":"10.1002\/14651858.CD010292.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.3899\/jrheum.100365","article-title":"Flexible dosed duloxetine in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial","volume":"37","author":"Arnold","year":"2010","journal-title":"Journal of Rheumatology"},{"key":"10.1002\/14651858.CD010292.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1097\/PSY.0b013e31825b9855","article-title":"The effect of duloxetine treatment on cognition in patients with fibromyalgia","volume":"74","author":"Mohs","year":"2012","journal-title":"Psychosomatic Medicine"},{"issue":"9","key":"10.1002\/14651858.CD010292.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1002\/art.27559","article-title":"Efficacy and safety of milnacipran 100 mg\/day in patients with fibromyalgia: results of a randomized, double-blind, placebo-controlled trial","volume":"62","author":"Arnold","year":"2010","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD010292.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1097\/AJP.0b013e3182510295","article-title":"Efficacy and safety of duloxetine 30 mg\/d in patients with fibromyalgia: a randomized, double-blind, placebo-controlled study","volume":"28","author":"Arnold","year":"2012","journal-title":"Clinical Journal of Pain"},{"key":"10.1002\/14651858.CD010292.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2147\/JPR.S43395","article-title":"Results of switching to milnacipran in fibromyalgia patients with an inadequate response to duloxetine: a phase IV pilot study","volume":"6","author":"Bateman","year":"2013","journal-title":"Journal of Pain Research"},{"issue":"4","key":"10.1002\/14651858.CD010292.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"851","DOI":"10.3899\/jrheum.090884","article-title":"A European multicenter randomized double-blind placebo-controlled monotherapy clinical trial of milnacipran in treatment of fibromyalgia","volume":"37","author":"Branco","year":"2010","journal-title":"Journal of Rheumatology"},{"issue":"1","key":"10.1002\/14651858.CD010292.pub2-BIB0009|cit9","first-page":"91","article-title":"A six-month double-blind, placebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia","volume":"30","author":"Chappell","year":"2009","journal-title":"International Journal of General Medicine"},{"issue":"11","key":"10.1002\/14651858.CD010292.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1016\/j.clinthera.2008.11.009","article-title":"Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial","volume":"30","author":"Clauw","year":"2008","journal-title":"Clinical Therapeutics"},{"key":"10.1002\/14651858.CD010292.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"R88","DOI":"10.1186\/ar4268","article-title":"Continuing efficacy of milnacipran following long-term treatment in fibromyalgia: a randomized trial","volume":"15","author":"Clauw","year":"2013","journal-title":"Arthritis Research & Therapy"},{"key":"10.1002\/14651858.CD010292.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"679","DOI":"10.2147\/JPR.S70200","article-title":"Efficacy of long-term milnacipran treatment in patients meeting different thresholds of clinically relevant pain relief: subgroup analysis of a randomized, double-blind, placebo-controlled withdrawal study","volume":"7","author":"Mease","year":"2014","journal-title":"Journal of Pain Research"},{"key":"10.1002\/14651858.CD010292.pub2-BIB0013|cit13","first-page":"S82","article-title":"A randomised controlled trial comparing duloxetine and acetyl L-carnitine in fibromyalgic patients: preliminary data","volume":"33","author":"Leombruni","year":"2015","journal-title":"Clinical and Experimental Rheumatology"},{"key":"10.1002\/14651858.CD010292.pub2-BIB0014|cit14","first-page":"E553","article-title":"Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial","volume":"16","author":"Matthey","year":"2013","journal-title":"Pain Physician"},{"issue":"2","key":"10.1002\/14651858.CD010292.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"398","DOI":"10.3899\/jrheum.080734","article-title":"The efficacy and safety of milnacipran for treatment of fibromyalgia. a randomized, double-blind, placebo-controlled trial","volume":"36","author":"Mease","year":"2009","journal-title":"Journal of Rheumatology"},{"key":"10.1002\/14651858.CD010292.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/s13075-015-0718-y","article-title":"A randomized, double-blind, placebo-controlled phase III trial of duloxetine in Japanese fibromyalgia patients","volume":"17","author":"Murakami","year":"2015","journal-title":"Arthritis Research & Therapy"},{"key":"10.1002\/14651858.CD010292.pub2-BIB0017|cit17","unstructured":"A study evaluating desvenlafaxine sustained release (DVS SR) in adult female outpatients with fibromyalgia clinicaltrials.gov\/ct2\/results?term=NCT00696787&Search=Search"},{"issue":"3","key":"10.1002\/14651858.CD010292.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.pain.2008.02.024","article-title":"Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial","volume":"136","author":"Russell","year":"2008","journal-title":"Pain"},{"key":"10.1002\/14651858.CD010292.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.jpain.2015.04.010","article-title":"Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial","volume":"16","author":"Staud","year":"2015","journal-title":"Journal of Pain"},{"issue":"10","key":"10.1002\/14651858.CD010292.pub2-BIB0020|cit20","first-page":"1975","article-title":"Efficacy of milnacipran in patients with fibromyalgia","volume":"32","author":"Gendreau","year":"2005","journal-title":"Journal of Rheumatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD010292.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1002\/hup.622","article-title":"A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia","volume":"19","author":"Vitton","year":"2004","journal-title":"Human Psychopharmacology"},{"key":"10.1002\/14651858.CD010292.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"79","DOI":"10.5664\/jcsm.5400","article-title":"The effects of milnacipran on dleep fisturbance in fibromyalgia: a randomized, double-blind, placebo-controlled, two-way crossover study","volume":"12","author":"Ahmed","year":"2016","journal-title":"Journal of Clinical Sleep Medicine"},{"key":"10.1002\/14651858.CD010292.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1097\/AJP.0b013e31827a784e","article-title":"Combining cognitive-behavioral therapy and milnacipran for fibromyalgia: a feasibility randomized-controlled trial","volume":"29","author":"Ang","year":"2013","journal-title":"Clinical Journal of Pain"},{"key":"10.1002\/14651858.CD010292.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.3899\/jrheum.101025","article-title":"Long term therapeutic response to milnacipran treatment for fibromyalgia. A European 1-year extension study following a 3-month study","volume":"38","author":"Branco","year":"2011","journal-title":"Journal of Rheumatology"},{"key":"10.1002\/14651858.CD010292.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/AJP.0b013e31819be587","article-title":"A 1-year safety and efficacy study of duloxetine in patients with fibromyalgia","volume":"25","author":"Chappell","year":"2009","journal-title":"Clinical Journal of Pain"},{"key":"10.1002\/14651858.CD010292.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/S0033-3182(98)71375-1","article-title":"An open clinical trial of venlafaxine treatment of fibromyalgia","volume":"39","author":"Dwight","year":"1998","journal-title":"Psychosomatics"},{"key":"10.1002\/14651858.CD010292.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1526-4637.2009.00755.x","article-title":"Durability of therapeutic response to milnacipran treatment for fibromyalgia. Results of a randomized, double-blind, monotherapy 6-month extension study","volume":"11","author":"Goldenberg","year":"2010","journal-title":"Pain Medicine"},{"key":"10.1002\/14651858.CD010292.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"398","DOI":"10.4088\/PCC.v09n0511g","article-title":"Effective treatment of fibromyalgia comorbid with premenstrual dysphoric disorder with a low dose of venlafaxine","volume":"9","author":"Hsiao","year":"2007","journal-title":"Primary Care Companion to the Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD010292.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.semarthrit.2008.11.001","article-title":"Long-term safety, tolerability, and efficacy of duloxetine in the treatment of fibromyalgia","volume":"39","author":"Mease","year":"2010","journal-title":"Seminars in Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD010292.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/j.jpain.2015.08.004","article-title":"Effect of milnacipran treatment on ventricular lactate in fibromyalgia: a randomized, double-blind, placebo-controlled trial","volume":"16","author":"Natelson","year":"2015","journal-title":"Journal of Pain"},{"key":"10.1002\/14651858.CD010292.pub2-BIB0031|cit31","unstructured":"Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) Versus Placebo in Peri- and Postmenopausal Women https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00369343?term=desvenlafaxine&cond=fibromyalgia&rank=4"},{"key":"10.1002\/14651858.CD010292.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/cpdd.271","article-title":"Clinical experience with desvenlafaxine in treatment of patients with fibromyalgia syndrome","volume":"6","author":"Allen","year":"2017","journal-title":"Clinical Pharmacology in Drug Development"},{"key":"10.1002\/14651858.CD010292.pub2-BIB0033|cit33","unstructured":"Fibromyalgia health outcome study on cost of treatments (REFLECTIONS) clinicaltrials.gov\/ct2\/results?term=NCT00725101&Search=Search"},{"key":"10.1002\/14651858.CD010292.pub2-BIB0034|cit34","unstructured":"Effect of milnacipran on pain processing and functional magnetic resonance imaging (fMRI) activation patterns in patients with fibromyalgia clinicaltrials.gov\/ct2\/results?term=NCT00793520&Search=Search"},{"key":"10.1002\/14651858.CD010292.pub2-BIB0035|cit35","unstructured":"The effect of milnacipran in patients with fibromyalgia clinicaltrials.gov\/ct2\/results?term=NCT01108731&Search=Search"},{"key":"10.1002\/14651858.CD010292.pub2-BIB0036|cit36","unstructured":"A study to evaluate the effects of milnacipran on pain processing and functional MRI in patients with fibromyalgia clinicaltrials.gov\/ct2\/results?term=NCT01173055&Search=Search"},{"key":"10.1002\/14651858.CD010292.pub2-BIB0037|cit37","unstructured":"The effects of milnacipran on sleep disturbance in fibromyalgia clinicaltrials.gov\/ct2\/results?term=NCT01234675&Search=Search"},{"key":"10.1002\/14651858.CD010292.pub2-BIB0038|cit38","unstructured":"Effects of milnacipran on widespread mechanical and thermal hyperalgesia of fibromyalgia patients clinicaltrials.gov\/ct2\/results?term=NCT01294059&Search=Search"},{"key":"10.1002\/14651858.CD010292.pub2-BIB0039|cit39","unstructured":"Long-term safety and efficacy study of milnacipran in pediatric patients with primary fibromyalgia clinicaltrials.gov\/ct2\/results?term=NCT01331109&Search=Search"},{"key":"10.1002\/14651858.CD010292.pub2-BIB0040|cit40","unstructured":"An extension study of duloxetine in fibromyalgia (extension of F1J-JE-HMGZ, NCT01552057) clinicaltrials.gov\/ct2\/results?term=NCT01621191&Search=Search"},{"issue":"5","key":"10.1002\/14651858.CD010292.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1185\/03007995.2012.677418","article-title":"Short-term (2-week) effects of discontinuing milnacipran in patients with fibromyalgia","volume":"28","author":"Saxe","year":"2012","journal-title":"Current Medical Research and Opinion"},{"key":"10.1002\/14651858.CD010292.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1345\/aph.1D112","article-title":"Venlafaxine treatment of fibromyalgia","volume":"37","author":"Sayar","year":"2003","journal-title":"Annals of Pharmacotherapy"},{"key":"10.1002\/14651858.CD010292.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1185\/03007995.2013.861812","article-title":"Milnacipran effects on 24-hour ambulatory blood pressure and heart rate in fibromyalgia patients: a randomized, placebo-controlled, dose-escalation study","volume":"30","author":"Trugman","year":"2014","journal-title":"Current Medical Research & Opinion"},{"key":"10.1002\/14651858.CD010292.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/jcpt.12216","article-title":"A systematic review of the efficacy of venlafaxine for the treatment of fibromyalgia","volume":"40","author":"Smith","year":"2015","journal-title":"Journal of clinical pharmacy and therapeutics"},{"key":"10.1002\/14651858.CD010292.pub2-BIB0045|cit45","first-page":"S105","article-title":"Venlafaxine in fibromyalgia: results of a randomized placebo-controlled randomized trial","volume":"52","author":"Ziljstra","year":"2002","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD010292.pub2-BIB0046|cit46","unstructured":"Pilot, opened, randomized clinical trial to assess the efficacy of duloxetine in the treatment of fibromialgy in patients with infection by HIV 1+ clinicaltrials.gov\/ct2\/results?term=NCT00552682&Search=Search"},{"key":"10.1002\/14651858.CD010292.pub2-BIB0047|cit47","unstructured":"Mechanism-based choice of therapy: can treatments success in fibromyalgia patients be coupled to psychophysical pain modulation profile? (MTF) clinicaltrials.gov\/ct2\/results?term=NCT01268631&Search=Search"},{"key":"10.1002\/14651858.CD010292.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"485272","DOI":"10.1155\/2013\/485272","article-title":"Treatment of fibromyalgia syndrome: recommendations of recent evidence-based interdisciplinary guidelines with special emphasis on complementary and alternative therapies","volume":"2013","author":"Ablin","year":"2013","journal-title":"Evidence-based Complementary and Alternative Medicine: ECAM"},{"issue":"7382","key":"10.1002\/14651858.CD010292.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1136\/bmj.326.7382.219","article-title":"Interaction revisited: the difference between two estimates","volume":"326","author":"Altman","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD010292.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1007\/s00103-008-0648-9","article-title":"Pharmacoepidemiological research with large health databases","volume":"51","author":"Andersohn","year":"2008","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz"},{"issue":"5","key":"10.1002\/14651858.CD010292.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"237","DOI":"10.4088\/PCC.08m00680","article-title":"Efficacy of duloxetine in patients with fibromyalgia: pooled analysis of 4 placebo-controlled clinical trials","volume":"11","author":"Arnold","year":"2009","journal-title":"Primary Care Companion to the Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD010292.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1002\/art.33360","article-title":"Development of responder definitions for fibromyalgia clinical trials","volume":"64","author":"Arnold","year":"2012","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD010292.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1097\/AJP.0b013e31828440ab","article-title":"A 3-year, open-label, flexible-dosing study of milnacipran for the treatment of fibromyalgia","volume":"29","author":"Arnold","year":"2013","journal-title":"Clinical Journal of Pain"},{"key":"10.1002\/14651858.CD010292.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12969-015-0025-9","article-title":"Preliminary experience using milnacipran in patients with juvenile fibromyalgia: lessons from a clinical trial program","volume":"13","author":"Arnold","year":"2015","journal-title":"Pediatric Rheumatology Online Journal"},{"key":"10.1002\/14651858.CD010292.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.3899\/jrheum.170098","article-title":"Adherence and persistence with drug therapy among fibromyalgia patients: data from a large health maintenance organization","volume":"10","author":"Ben-Ami Shor","year":"2017","journal-title":"Journal of Rheumatology"},{"key":"10.1002\/14651858.CD010292.pub2-BIB0056|cit56","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009796.pub2","article-title":"Cognitive behavioural therapies for fibromyalgia syndrome","volume":"22","author":"Bernardy","year":"2017","journal-title":"European Journal of Pain"},{"key":"10.1002\/14651858.CD010292.pub2-BIB0057|cit57","unstructured":"Research www.bmj.com\/about-bmj\/resources-authors\/article-types\/research"},{"issue":"12 Suppl","key":"10.1002\/14651858.CD010292.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/j.amjmed.2009.09.008","article-title":"Pathophysiology of fibromyalgia","volume":"122","author":"Bradley","year":"2009","journal-title":"American Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD010292.pub2-BIB0059|cit59","first-page":"16","article-title":"Drugs to treat fibromyalgia - the transatlantic difference","volume":"11","author":"Briley","year":"2010","journal-title":"Current Opinion in Investigational Drugs"},{"key":"10.1002\/14651858.CD010292.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.jpain.2015.06.004","article-title":"Bidirectional association between depression and fibromyalgia syndrome: a nationwide longitudinal study","volume":"16","author":"Chang","year":"2015","journal-title":"Journal of Pain"},{"key":"10.1002\/14651858.CD010292.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.jpain.2010.01.267","article-title":"The association between incident self-reported fibromyalgia and nonpsychiatric factors: 25-years follow-up of the Adventist Health Study","volume":"11","author":"Choi","year":"2010","journal-title":"The Journal of Pain"},{"key":"10.1002\/14651858.CD010292.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/00124743-199512000-00004","article-title":"The overlap between fibromyalgia and inflammatory rheumatic disease: when and why does it occur?","volume":"1","author":"Clauw","year":"1995","journal-title":"Journal of Clinical Rheumatology"},{"key":"10.1002\/14651858.CD010292.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1001\/jama.2014.3266","article-title":"Fibromyalgia: a clinical review","volume":"311","author":"Clauw","year":"2014","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD010292.pub2-BIB0064|cit64","volume-title":"Statistical power analysis for the behavioral sciences","author":"Cohen","year":"1988"},{"issue":"10","key":"10.1002\/14651858.CD010292.pub2-BIB0065|cit65","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008244","article-title":"Milnacipran for pain in fibromyalgia in adults","author":"Cording","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD010292.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1055\/s-2006-958723","article-title":"Hypertension induced by regular doses of milnacipran: a case report","volume":"40","author":"Toledo Ferraz Alves","year":"2007","journal-title":"Pharmacopsychiatry"},{"key":"10.1002\/14651858.CD010292.pub2-BIB0067|cit67","unstructured":"Deeks JJ Higgins JPT Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD010292.pub2-BIB0068|cit68","unstructured":"Department of health & Human Services NDA Approval www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2008\/022148s000ltr.pdf"},{"key":"10.1002\/14651858.CD010292.pub2-BIB0069|cit69","unstructured":"Department of health & Human Services NDA approval https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2009\/022256ltr.pdf"},{"issue":"3","key":"10.1002\/14651858.CD010292.pub2-BIB0070|cit70","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012332.pub2","article-title":"Oral nonsteroidal anti-inflammatory drugs for fibromyalgia in adults","author":"Derry","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD010292.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.pain.2009.08.019","article-title":"Interpreting the clinical importance of group differences in chronic pain clinical trials: IMMPACT recommendations","volume":"146","author":"Dworkin","year":"2009","journal-title":"Pain"},{"key":"10.1002\/14651858.CD010292.pub2-BIB0072|cit72","unstructured":"European Medicines Agency Refusal assessment report for Cymbalta. International non-proprietary name\/common name: (duloxetine hydrochloride) Procedure No. EMEA\/H\/C\/572\/II\/26 Available at www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Assessment_Report_-_Variation\/human\/000572\/WC500076168.pdf"},{"key":"10.1002\/14651858.CD010292.pub2-BIB0073|cit73","unstructured":"European Medicines Agency Refusal assessment report for milnacipran Pierre Fabre Medicament. International non-proprietary name: milnacipran. Procedure No. EMEA\/H\/C\/001034 www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/001034\/WC500089828.pdf"},{"key":"10.1002\/14651858.CD010292.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11136-013-0443-4","article-title":"Don\u2019t middle your MIDs: regression to the mean shrinks estimates of minimally important differences","volume":"23","author":"Fayers","year":"2014","journal-title":"Quality Life Research"},{"issue":"4","key":"10.1002\/14651858.CD010292.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/s00296-010-1713-x","article-title":"Individuals with fibromyalgia and depression: findings from a nationally representative Canadian survey","volume":"32","author":"Fuller-Thomson","year":"2012","journal-title":"Rheumatology International"},{"key":"10.1002\/14651858.CD010292.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/00004850-200501000-00010","article-title":"Imputing response rates from means and standard deviations in meta-analyses","volume":"20","author":"Furukawa","year":"2005","journal-title":"International Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD010292.pub2-BIB0077|cit77","unstructured":"McMaster University (developed by Evidence Prime) GRADEpro GDT 2015"},{"key":"10.1002\/14651858.CD010292.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD010292.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2147\/DHPS.S7634","article-title":"Antidepressant-associated sexual dysfunction: impact, effects, and treatment","volume":"10","author":"Higgins","year":"2010","journal-title":"Drug Healthcare and Patient Safety"},{"key":"10.1002\/14651858.CD010292.pub2-BIB0080|cit80","unstructured":"Higgins JPT Deeks JJ Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"23","key":"10.1002\/14651858.CD010292.pub2-BIB0081|cit81","first-page":"383","article-title":"Fibromyalgia syndrome: classification, diagnosis, and treatment","volume":"106","author":"H\u00e4user","year":"2009","journal-title":"Deutsches \u00c4rzteblatt International\u00a0"},{"issue":"8","key":"10.1002\/14651858.CD010292.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/acr.20328","article-title":"Emotional, physical and sexual abuse in fibromyalgia syndrome - a systematic review with meta-analysis","volume":"63","author":"H\u00e4user","year":"2011","journal-title":"Arthritis Care and Research"},{"key":"10.1002\/14651858.CD010292.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jpain.2010.01.002","article-title":"Comparative efficacy and harms of duloxetine, milnacipran, and pregabalin in fibromyalgia syndrome","volume":"6","author":"H\u00e4user","year":"2010","journal-title":"Journal of Pain"},{"issue":"3","key":"10.1002\/14651858.CD010292.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"R79","DOI":"10.1186\/ar3002","article-title":"Efficacy of different types of aerobic exercise in fibromyalgia syndrome: a systematic review and meta-analysis of randomised controlled trials","volume":"12","author":"H\u00e4user","year":"2010","journal-title":"Arthritis Research Therapy"},{"key":"10.1002\/14651858.CD010292.pub2-BIB0085|cit85","doi-asserted-by":"crossref","unstructured":"H\u00e4user W Bartram-Wunn E Bartram C T\u00f6lle TR Placebo responders in randomized controlled drug trials of fibromyalgia syndrome: systematic review and meta-analysis Schmerz 2011 25 19 31","DOI":"10.1007\/s00482-011-1106-4"},{"key":"10.1002\/14651858.CD010292.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1097\/AJP.0b013e3182321ad8","article-title":"Adverse events attributable to nocebo in randomized controlled drug trials in fibromyalgia syndrome and painful diabetic peripheral neuropathy: systematic review","volume":"28","author":"H\u00e4user","year":"2012","journal-title":"Clinical Journal of Pain"},{"key":"10.1002\/14651858.CD010292.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.pain.2013.03.034","article-title":"Posttraumatic stress disorder in fibromyalgia syndrome: prevalence, temporal relationship between posttraumatic stress and fibromyalgia symptoms, and impact on clinical outcome","volume":"154","author":"H\u00e4user","year":"2013","journal-title":"Pain"},{"issue":"1","key":"10.1002\/14651858.CD010292.pub2-BIB0088|cit88","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010292","article-title":"Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia syndrome","author":"H\u00e4user","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD010292.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1002\/j.1532-2149.2014.00453.x","article-title":"Fibromyalgia syndrome - a somaform disorder","volume":"18","author":"H\u00e4user","year":"2014","journal-title":"European Journal of Pain"},{"key":"10.1002\/14651858.CD010292.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"15022","DOI":"10.1038\/nrdp.2015.22","article-title":"Fibromyalgia","volume":"1","author":"H\u00e4user","year":"2015","journal-title":"Nature Reviews Disease Primers"},{"key":"10.1002\/14651858.CD010292.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s00482-014-1462-y","article-title":"Methodology of the development of the updated LONTS guidelines for long-term administration of opioids in noncancer pain","volume":"29","author":"H\u00e4user","year":"2015","journal-title":"Schmerz"},{"key":"10.1002\/14651858.CD010292.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jpain.2017.08.009","article-title":"Unravelling fibromyalgia - steps towards individualized management","volume":"19","author":"H\u00e4user","year":"2018","journal-title":"Journal of Pain"},{"key":"10.1002\/14651858.CD010292.pub2-BIB0093|cit93","unstructured":"International Council for Harmonisation Medical Dictionary for Regulatory Activities Version 19.1 www.meddra.org\/news-and-events\/news\/all-translations-meddra-version-191-are-now-available 2016 2016"},{"issue":"9","key":"10.1002\/14651858.CD010292.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1345\/aph.1P218","article-title":"Milnacipran for treatment of fibromyalgia","volume":"44","author":"Kyle","year":"2010","journal-title":"Annals of Pharmacotherapy"},{"key":"10.1002\/14651858.CD010292.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1007\/s00482-010-0937-8","article-title":"Influence of depression on fibromyalgia: a systematic review","volume":"24","author":"Lange","year":"2010","journal-title":"Schmerz"},{"key":"10.1002\/14651858.CD010292.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00296-010-1678-9","article-title":"Candidate gene studies of fibromyalgia: a systematic review and meta-analysis","volume":"32","author":"Lee","year":"2012","journal-title":"Rheumatology International"},{"key":"10.1002\/14651858.CD010292.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s00296-016-3468-5","article-title":"Comparative efficacy and tolerability of duloxetine, pregabalin, and milnacipran for the treatment of fibromyalgia: a Bayesian network meta-analysis of randomized controlled trials","volume":"36","author":"Lee","year":"2016","journal-title":"Rheumatology International"},{"issue":"3","key":"10.1002\/14651858.CD010292.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1093\/rheumatology\/40.3.290","article-title":"Cerebrospinal fluid biogenic amine metabolites, plasma-rich platelet serotonin and [3H]imipramine reuptake in the primary fibromyalgia syndrome","volume":"40","author":"Legangneux","year":"2001","journal-title":"Rheumatology"},{"key":"10.1002\/14651858.CD010292.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"263","DOI":"10.18553\/jmcp.2016.22.3.263","article-title":"Treatment patterns associated with ACR-recommended medications in the management of fibromyalgia in the United States","volume":"22","author":"Liu","year":"2013","journal-title":"Journal of Managed Care & Specialty Pharmacy"},{"issue":"2014","key":"10.1002\/14651858.CD010292.pub2-BIB0100|cit100","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007115","article-title":"Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia","author":"Lunn","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD010292.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1136\/annrheumdis-2016-209724","article-title":"EULAR recommendations for management of fibromyalgia","volume":"76","author":"Macfarlane","year":"2017","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"10","key":"10.1002\/14651858.CD010292.pub2-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.3899\/jrheum.090367","article-title":"Fibromyalgia syndrome module at OMERACT 9: domain construct","volume":"36","author":"Mease","year":"2009","journal-title":"Journal of Rheumatology"},{"key":"10.1002\/14651858.CD010292.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1177\/1759720X13483894","article-title":"Milnacipran combined with pregabalin in fibromyalgia: a randomized, open-label study evaluating the safety and efficacy of adding milnacipran in patients with incomplete response to pregabalin","volume":"5","author":"Mease","year":"2013","journal-title":"Therapeutic Advances in Musculoskeletal Diseases"},{"key":"10.1002\/14651858.CD010292.pub2-BIB0104|cit104","volume-title":"Systematic Reviews in Pain Research: Methodology Refined","author":"Moore","year":"2008"},{"issue":"3","key":"10.1002\/14651858.CD010292.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.pain.2010.05.011","article-title":"\"Evidence\" in chronic pain--establishing best practice in the reporting of systematic reviews","volume":"150","author":"Moore","year":"2010","journal-title":"Pain"},{"issue":"2","key":"10.1002\/14651858.CD010292.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.pain.2009.08.007","article-title":"Clinical effectiveness: an approach to clinical trial design more relevant to clinical practice, acknowledging the importance of individual differences","volume":"149","author":"Moore","year":"2010","journal-title":"Pain"},{"key":"10.1002\/14651858.CD010292.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.pain.2010.02.039","article-title":"Fibromyalgia: moderate and substantial pain intensity reduction predicts improvement in other outcomes and substantial quality of life gain","volume":"149","author":"Moore","year":"2010","journal-title":"Pain"},{"key":"10.1002\/14651858.CD010292.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.pain.2011.10.004","article-title":"Estimate at your peril: imputation methods for patient withdrawal can bias efficacy outcomes in chronic pain trials using responder analyses","volume":"153","author":"Moore","year":"2012","journal-title":"Pain"},{"key":"10.1002\/14651858.CD010292.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/acr.20118","article-title":"Association between physical exercise, body mass index, and risk of fibromyalgia: longitudinal data from the Norwegian Nord-Tr\u00f8ndelag Health Study","volume":"62","author":"Mork","year":"2010","journal-title":"Arthritis Care & Research"},{"key":"10.1002\/14651858.CD010292.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/art.33346","article-title":"Sleep problems and risk of fibromyalgia: longitudinal data on an adult female population in Norway","volume":"64","author":"Mork","year":"2012","journal-title":"Arthritis & Rheumatism"},{"key":"10.1002\/14651858.CD010292.pub2-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1080\/14397595.2016.1245237","article-title":"An open-label, long-term, phase III extension trial of duloxetine in Japanese patients with fibromyalgia","volume":"27","author":"Murakami","year":"2017","journal-title":"Modern Rheumatology"},{"issue":"4","key":"10.1002\/14651858.CD010292.pub2-BIB0112|cit112","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006192","article-title":"Anti-depressants and centrally active agents for fibromyalgia syndrome","author":"Nishishinya","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"10","key":"10.1002\/14651858.CD010292.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1097\/00005650-200110000-00002","article-title":"Relation of distribution- and anchor-based approaches in interpretation of changes in health-related quality of life","volume":"39","author":"Norman","year":"2001","journal-title":"Medical Care"},{"key":"10.1002\/14651858.CD010292.pub2-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1136\/annrheumdis-2011-201249","article-title":"Comparative efficacy of pharmacological and non-pharmacological interventions in fibromyalgia syndrome: network meta-analysis","volume":"72","author":"N\u00fcesch","year":"2013","journal-title":"Annals of Rheumatic Diseases"},{"key":"10.1002\/14651858.CD010292.pub2-BIB0115|cit115","first-page":"15","article-title":"Milnacipran for the management of fibromyalgia syndrome","volume":"3","author":"Ormseth","year":"2010","journal-title":"Journal of Pain Research"},{"key":"10.1002\/14651858.CD010292.pub2-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1007\/s00482-017-0201-6","article-title":"General treatment principles, coordination of care and patient education in fibromyalgia syndrome: updated guidelines 2017 and overview of systematic review articles","volume":"31","author":"Petzke","year":"2017","journal-title":"Schmerz"},{"key":"10.1002\/14651858.CD010292.pub2-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1007\/s11916-013-0356-5","article-title":"Worldwide epidemiology of fibromyalgia","volume":"17","author":"Queiroz","year":"2013","journal-title":"Current Pain and Headache Reports"},{"key":"10.1002\/14651858.CD010292.pub2-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1002\/syn.20893","article-title":"Sleep disturbance associated with an enhanced orexinergic system induced by chronic treatment with paroxetine and milnacipran","volume":"65","author":"Rahmadi","year":"2011","journal-title":"Synapse"},{"key":"10.1002\/14651858.CD010292.pub2-BIB0119|cit119","unstructured":"Nordic Cochrane Centre, The Cochrane Collaboration Review Manager 5 (RevMan 5) 2014"},{"issue":"4","key":"10.1002\/14651858.CD010292.pub2-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1086\/650004","article-title":"Comparative efficacy versus effectiveness of initial antiretroviral therapy in clinical trials versus routine care","volume":"15","author":"Routman","year":"2010","journal-title":"Clinical Infectious Diseases"},{"issue":"5","key":"10.1002\/14651858.CD010292.pub2-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/art.1780350509","article-title":"Cerebrospinal fluid biogenic amine metabolites in fibromyalgia\/fibrositis syndrome and rheumatoid arthritis","volume":"35","author":"Russell","year":"1992","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD010292.pub2-BIB0122|cit122","unstructured":"Sch\u00fcnemann HJ Oxman AD Vist GE Higgins JPT Deeks JJ Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD010292.pub2-BIB0123|cit123","volume-title":"Fibrositis and other diffuse musculoskeletal syndromes. Textbook of Reumathology","author":"Smythe","year":"1981"},{"key":"10.1002\/14651858.CD010292.pub2-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1177\/2045125312472890","article-title":"A review of the suitability of duloxetine and venlafaxine for use in patients with depression in primary care with a focus on cardiovascular safety, suicide and mortality due to antidepressant overdose","volume":"3","author":"Taylor","year":"2013","journal-title":"Therapeutic Advances in Psychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD010292.pub2-BIB0125|cit125","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009807","article-title":"Monoamine oxidase inhibitors (MAOIs) for fibromyalgia syndrome","author":"Tort","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD010292.pub2-BIB0126|cit126","first-page":"391","article-title":"Efficacy and safety of duloxetine in fibromyalgia","volume":"161","author":"Ursini","year":"2010","journal-title":"Clinical Therapeutics"},{"key":"10.1002\/14651858.CD010292.pub2-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/jcpt.12216","article-title":"A systematic review of the efficacy of venlafaxine for the treatment of fibromyalgia","volume":"40","author":"VanderWeide","year":"2015","journal-title":"Journal of Clinical Pharmacy and Therapeutics"},{"key":"10.1002\/14651858.CD010292.pub2-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1176\/appi.ajp.2013.13050709","article-title":"Antidepressant-induced liver injury: a review for clinicians","volume":"171","author":"Voican","year":"2014","journal-title":"American Journal of Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD010292.pub2-BIB0129|cit129","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011735","article-title":"Selective serotonin reuptake inhibitors for fibromyalgia syndrome","author":"Walitt","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"12","key":"10.1002\/14651858.CD010292.pub2-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1002\/art.1780331217","article-title":"The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee","volume":"33","author":"Wolfe","year":"1990","journal-title":"Arthritis and Rheumatism"},{"issue":"5","key":"10.1002\/14651858.CD010292.pub2-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/acr.20140","article-title":"The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity","volume":"62","author":"Wolfe","year":"2010","journal-title":"Arthritis and Rheumatism"},{"issue":"2","key":"10.1002\/14651858.CD010292.pub2-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.pain.2010.09.027","article-title":"The development of fibromyalgia - I: examination of rates and predictors in patients with rheumatoid arthritis (RA)","volume":"152","author":"Wolfe","year":"2011","journal-title":"Pain"},{"issue":"6","key":"10.1002\/14651858.CD010292.pub2-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.3899\/jrheum.100594","article-title":"Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR preliminary diagnostic criteria for fibromyalgia","volume":"38","author":"Wolfe","year":"2011","journal-title":"Journal of Rheumatology"},{"key":"10.1002\/14651858.CD010292.pub2-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1002\/acr.21931","article-title":"Fibromyalgia prevalence, somatic symptom reporting, and the dimensionality of polysymptomatic distress: results from a survey of the general population","volume":"64","author":"Wolfe","year":"2013","journal-title":"Arthritis Care & Research"},{"key":"10.1002\/14651858.CD010292.pub2-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/j.1532-2149.2012.00234.x","article-title":"Longitudinal patterns of analgesic and central acting drug use and associated effectiveness in fibromyalgia","volume":"17","author":"Wolfe","year":"2013","journal-title":"European Journal of Pain"},{"key":"10.1002\/14651858.CD010292.pub2-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.semarthrit.2016.08.012","article-title":"2016 Revisions to the 2010\/2011 fibromyalgia diagnostic criteria","volume":"46","author":"Wolfe","year":"2016","journal-title":"Seminars in Arthritis and Rheumatism"},{"issue":"1","key":"10.1002\/14651858.CD010292.pub2-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/0049-0172(81)90096-2","article-title":"Primary fibromyalgia (fibrositis): clinical study of 50 patients with matched normal controls","volume":"11","author":"Yunus","year":"1981","journal-title":"Seminars in Arthritis and Rheumatism"},{"issue":"5","key":"10.1002\/14651858.CD010292.pub2-BIB0138|cit138","first-page":"115","article-title":"Primary fibromyalgia","volume":"25","author":"Yunus","year":"1982","journal-title":"American Family Physician"},{"issue":"8","key":"10.1002\/14651858.CD010292.pub2-BIB0139|cit139","first-page":"21","article-title":"Primary fibromyalgia syndrome: current concepts","volume":"10","author":"Yunus","year":"1984","journal-title":"Comprehensive Therapy"},{"key":"10.1002\/14651858.CD010292.pub2-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.semarthrit.2007.09.003","article-title":"Central sensitivity syndromes: a new paradigm and group nosology for fibromyalgia and overlapping conditions, and the related issue of disease versus illness","volume":"37","author":"Yunus","year":"2008","journal-title":"Seminars in Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD010292.pub2-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s00482-017-0202-5","article-title":"Etiology and pathophysiology of fibromyalgia syndrome: updated guidelines 2017, overview of systematic review articles and overview of studies on small fiber neuropathy in FMS subgroups","volume":"31","author":"\u00dc\u00e7eyler","year":"2017","journal-title":"Schmerz"},{"issue":"10","key":"10.1002\/14651858.CD010292.pub2-BIB0142|cit142","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010782.pub2","article-title":"Anticonvulsants for fibromyalgia","author":"\u00dc\u00e7eyler","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD010292.pub2\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,13]],"date-time":"2021-09-13T13:44:40Z","timestamp":1631540680000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD010292.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Pain, Palliative and Supportive Care Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2018,2,28]]},"references-count":142,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2020,7]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd010292.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,28]]}}}